NCT02488694View on ClinicalTrials.gov

Maintaining ERBB Blockade in EGFR-mutated Lung Cancer

PHASE2TerminatedINTERVENTIONAL

Enrollment

4

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions

Non-small-cell Lung Cancer With Somatic EGFR Mutations

Interventions

DRUG

Afatinib

40 mg/d

DRUG

Pemetrexed

500 mg/m² i.v. on d1 of each 21-day cycle

Trial Locations (1)

Unknown

Universitätsklinikum Essen, Essen

Sponsors

Collaborators (1)

Boehringer Ingelheim

All Listed Sponsors

collaborator

Boehringer Ingelheim

INDUSTRY

lead

AIO-Studien-gGmbH

OTHER

NCT02488694 - Maintaining ERBB Blockade in EGFR-mutated Lung Cancer | Biotech Hunter | Biotech Hunter